(2S,3S)-2-(Diphenylmethyl)-N-{[2-methoxy-5-(1-methylethyl)-phenyl]-methyl}-1-azabicyclo[2.2.2]octan-3-amine
CAS : 147116-64-1
Ref. 3D-FD157384
Taille indéfinie | Arrêté |
Informations sur le produit
- (2S,3S)-2-(Diphenylmethyl)-N-(5-isopropyl-2-methoxybenzyl)quinuclidin-3-amine
- (2S,3S)-2-(Diphenylmethyl)-N-[[2-methoxy-5-(1-methylethyl)phenyl]methyl]-1-azabicyclo[2.2.2]octan-3-amine
- 1-Azabicyclo[2.2.2]octan-3-amine, 2-(diphenylmethyl)-N-[[2-methoxy-5-(1-methylethyl)phenyl]methyl]-, (2S,3S)-
- 1-Azabicyclo[2.2.2]octan-3-amine, 2-(diphenylmethyl)-N-[[2-methoxy-5-(1-methylethyl)phenyl]methyl]-, (2S-cis)-
- Cj 11974
- Ezlopitant
(2S,3S)-2-(Diphenylmethyl)-N-{[2-methoxy-5-(1-methylethyl)-phenyl]-methyl}-1-azabicyclo[2.2.2]octan-3-amine is a pharmaceutical drug that is used in the treatment of inflammatory bowel disease and cancer. It has been shown to inhibit epidermal growth factor (EGF) receptor tyrosine kinase activity and to have an antimuscarinic effect. The drug binds to the neurokinin 1 receptor (NK1R) and blocks its activity, which leads to the suppression of gastrointestinal motility and chronic bronchitis symptoms. This drug also decreases blood pressure in hypertensive rats, which may be due to its ability to inhibit angiotensin II formation by blocking the conversion of angiotensin I into angiotensin II.